Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

-- 152,873 (25,450) 127,423 --------------------------------- --------------------------------------- EXPENSES License and royalty fees 5,474 - 5,474 Cost of products sold 49,648 (896) b 48,752 Research and development 12,930 (1,152) c 11,778 Selling, general and administrative 41,178 (5,131) d 36,047 Depreciation and amortization 16,560 (14,834) e 1,726 In-process research and development - - - --------------------------------- --------------------------------------- 125,790 (22,013) 103,777 --------------------------------- --------------------------------------- Operating income (loss) 27,083 (3,437) 23,646 --------------------------------- --------------------------------------- Other income (expenses): Foreign exchange (loss) gain (709) 709 g - Investment and other income (loss) (615) 676 h 61 Loss on sale/write-down of investments - - - Interest expense on long-term debt (19,685) 1,368 j (18,317) --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- (21,009) 2,753 (18,256) --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- Income (loss) before income taxes 6,074 (684) 5,390 Income tax expense (recovery) 5,507 765 k 6,272 ----------------------------
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
(Date:8/18/2014)... Dallas, Texas (PRWEB) August 19, 2014 ... China Linalool Industry” is a professional and in-depth ... report provides basic Linalool information, including its ... well as industry overview. This research covers the ... well as global industry analysis covering macroeconomic environment ...
(Date:8/18/2014)... 18, 2014   Sterne, Kessler, Goldstein & Fox ... Washington, DC , announced today that it ... (IPR) with the U.S. Patent and Trademark Office ... BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions aim ... Myriad Genetics, Inc. These patents have been asserted against ...
(Date:8/18/2014)... , August 18, 2014 ... Bioreactor Systems Market, By Application (Municipal Wastewater Treatment ... Flat Sheet and Multi Tubular), By Configuration (Internal/Submerged ... 2019", published by MarketsandMarkets, The market for membrane ... by 2019, growing at a CAGR of 15.28% ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... cell technology to battle ... ... Bio, Inc.,announced today that John T. Dimos, Ph.D., first author of ... Can Be Differentiated into Motor Neurons," will join its team of,scientists ...
... Aug. 6 NxStage Medical, Inc.,(Nasdaq: NXTM ... announced that Jeffrey H. Burbank, Chief Executive Officer ... the following schedule,of investor conferences. Where possible, a ... http://www.nxstage.com/ir.cfm at the time of each,conference., ...
... by 11% Discovery ... Products and Services Growth -, HOPKINTON, Mass., Aug. 6 ... quarter financial,results for 2008. Revenues were $34.0 million for the quarter, ... Revenues were impacted,by a $3.5 million decline from 2007 in collaboration-related ...
Cached Biology Technology:iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits 2NxStage Announces Investor Conference Schedule 2Caliper Life Sciences Reports Second Quarter 2008 Results 2Caliper Life Sciences Reports Second Quarter 2008 Results 3Caliper Life Sciences Reports Second Quarter 2008 Results 4Caliper Life Sciences Reports Second Quarter 2008 Results 5Caliper Life Sciences Reports Second Quarter 2008 Results 6Caliper Life Sciences Reports Second Quarter 2008 Results 7Caliper Life Sciences Reports Second Quarter 2008 Results 8Caliper Life Sciences Reports Second Quarter 2008 Results 9
(Date:8/19/2014)... 2014 Smart Technology Sector improves ... as latest developments, ad campaigns and partnerships are announced: ... EBAY ), Amazon.com Inc. (NASDAQ: AMZN ), ... (NASDAQ: GOOG ) and Mastercard Incorporated (NYSE: ... authentication company focused on the growing m-commerce market releases ...
(Date:8/19/2014)... study of 9- and 10-year-olds finds that those who ... white-matter tracts in the brain than their peers who ... axons that carry nerve signals from one brain region ... faster and more efficient nerve activity. , The ... in Human Neuroscience. , "Previous studies suggest that ...
(Date:8/18/2014)... The specific composition of bacterial species in a person,s ... Campylobacter , the most common cause of human bacterial ... mBio , the online open-access journal of the American ... Campylobacter infection can yield lasting changes to one,s ... a long time that the microbiota, or microorganisms in ...
Breaking Biology News(10 mins):Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7Physically fit kids have beefier brain white matter than their less-fit peers 2Physically fit kids have beefier brain white matter than their less-fit peers 3What's in your gut? Certain bacteria may influence susceptibility to infection 2
... , LOS ANGELES (Jan. 16, 2013) In a ... known as status epilepticus, researchers reported today that new ... so, it would have to work directly to antagonize ... activity and memory function in the brain. "Despite ...
... found in Antarctica,s seabed sediments offer new clues about the ... and help scientists make better predictions about future sea-level rise. ... be vulnerable to regional climate warming and changes in ocean ... a team of researchers from British Antarctic Survey (BAS), ...
... provider of scientific, technical and medical information products and ... new journal, Journal of Unconventional Oil and Gas ... is to publish world-class science focusing on recent ... evaluation, development and management of unconventional resources for researchers ...
Cached Biology News:Promising new finding for therapies to treat persistent seizures in epileptic patients 2New Antarctic geological timeline aids future sea-level predictions 2New Antarctic geological timeline aids future sea-level predictions 3
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
WTAP Antibody...
Biology Products: